Merck KGaA Announces New Structure for Pharma Ethicals, Completes Global Management Team

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
Merck KGaA Announces New Structure for Pharma Ethicals, Completes Global Management Team
    DARMSTADT, Germany, April 18 /PRNewswire/ -- Merck KGaA today announced
the new organizational structure for its largest division, Ethical
Pharmaceuticals. The change also includes the promotion of four executives to
newly created positions, effective June 1, 2002.
    The goal of the new structure is to transform Merck's Ethicals Division
into a global business delivering innovative, patented pharmaceuticals. The
focus will be on the development and worldwide marketing of treatments for
diabetes and cancer, both areas of high medical need.
    The changes announced today are the logical progression from the October
1, 2001, appointment of Matthew W. Emmens as Head of the company's global
Ethicals Division. Emmens formally joined the Executive Board of Merck KGaA in
March 2002.
    "In the future, we can only expect an appropriate payback on our
investments in research and development if we realign the organization so that
we can launch our new and innovative drugs simultaneously in the major
countries of the world," Emmens said. "This new structure and the management
appointments that complete the new organizational chart should allow us to
accomplish that goal."
    Merck's Ethicals Division had sales of EUR 2 billion in 2001. It currently
has 19 compounds in clinical phase II or phase III development, including
eight in oncology and three to treat metabolic disorders and diabetes. Merck
anticipates the introduction of its first cancer drug, the monoclonal antibody
cetuximab (C225), in the European markets in 2003.
    The new Ethicals Executive Committee members and their titles:

     *  Matthew W. Emmens, President
     *  Inge Lues, Vice President Global Preclinical R&D
     *  Garry Neil, Vice President Global Clinical R&D
     *  Alfred Koch, Vice President Production & Supply Chain (formerly
        General Manager, Merck Brazil)
     *  Jon Stonehouse, Vice President Business Development & Integration
        (formerly VP Licensing, Business Strategy & IT, EMD Pharmaceuticals)
     *  Richard Douge, Vice President Marketing & Pharma International
        (formerly Head of Merck Pharma Ethicals, France)
     *  Nancy Wysenski, President EMD Pharmaceuticals, U.S.
     *  Jean Noel Treilles, President Merck France
     *  Klaus Falk, Vice President Europe (formerly General Manager, Merck
        Argentina)

    Merck's five Business Areas that corresponded to clinical indications have
been reduced to three and renamed to Therapeutic Areas:

     *  Andre Meynaud, formerly Head, Business Area Team Metabolic Disorders,
        will be appointed Vice President Therapeutic Area Diabetes.
     *  Bernhard Ehmer, formerly Head, Business Area Team Oncology, will be
        named Vice President Therapeutic Area Oncology.
     *  Wilfried H. Meyer, formerly Head, Business Area Team Cardiovascular,
        will be named Vice President, Established Products, under which
        Cardiovascular and Central nervous system have been grouped together.

    Merck's high potential drug candidates will be managed separately within
Business Development. The fully owned subsidiaries Theramex (Women's Health,
Monaco) and Dey (Respiratory Diseases, Napa Valley, USA) will remain self-
standing units.

    All Merck Press Releases are distributed by e-mail at the same time they
become available on the Merck Website. Please go to
http://www.merck.de/subscribe to register online, change your selection or
discontinue this service. In case of questions, please contact the Media
Hotline at: +49-0-6151-72-5000.
    With more than 34,000 employees in 55 countries, the Merck Group generated
sales of EUR 7.5 billion in 2001. Founded in 1668 in Darmstadt, Germany, the
company aims to be a world leader in its core businesses of pharmaceuticals
and chemicals. The Merck Group strongly believes the key to its long-term
business success is innovative products created by entrepreneurial and
talented employees. Merck groups its operating activities under Merck KGaA, in
which the Merck family holds 74% and the remaining 26% is publicly traded. The
former U.S. subsidiary, Merck & Co., has been a completely independent company
since 1917.
SOURCE Merck KGaA
http://www.merck.de/subscribe
CONTACT:
Phyllis Carter of Merck KGaA,
+49-0-61-51-72-7144